Systematic review evaluates the efficacy and safety of anti-GD2 monoclonal antibodies combined with GM-CSF in neuroblastoma, suggesting beneficial therapeutic value.
To conduct a systematic review and meta-analysis evaluating the efficacy and safety of anti-GD2 monoclonal antibody therapy combined with GM-CSF in patients with neuroblastoma, with the aim of clarifying its therapeutic value.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: